US EditionEdison Continues to Support Oryzon for the Potential of Vafidemstat in Limit Personality Disorder
Summary by bolsamania.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
“There is an important medical need not covered in the PLP, where clinicians should resort to antipsychotics or mood stabilizers without indication, with limited efficacy,” explains Prakash. The expert considers that vafidemstat could become a relevant option, especially because of its novel epigenetic mechanism and its positive effect on symptoms such as agitation and aggressiveness, which affect about 70% of patients and constitute one of the …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
